Preferred reporting items for comprehensive evaluation of Chinese patent medicine (PRICE-CPM)_Chinese Journal of Evidence-Based Medicine

Authors：

 Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences ,  Dongzhimen Hospital of Beijing University of Chinese Medicine , Guidelines and Standards Research Center of Chinese Medical Association Publishing House , China Information Association for Traditional Chinese Medicine and Pharmacy Clinical Research Information Association , Branch of Chinese Medicine of China Association for Standardization

Corresponding author：

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Email: wangyanping4816@163.com; Dongzhimen Hospital of Beijing University of Chinese Medicine, Email: shanghongcai@126.com

Keywords：

Chinese patent medicine; Comprehensive evaluation; Checklist of report; Report specification

DOI：

10.7507/1672-2531.202203157

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The preferred reporting items for comprehensive evaluation of Chinese patent medicine (PRICE-CPM) were developed, and comprised six domains, 21 items and 72 sub-items. The EQUATOR collaboration network for the formulation and revision of reporting specifications was referred to and the final report list items were established by adopting the literature analysis method, the expert committee discussion and the Delphi method, and considering the characteristics of CPM evaluation.

Citation： Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Dongzhimen Hospital of Beijing University of Chinese Medicine, Guidelines and Standards Research Center of Chinese Medical Association Publishing House, China Information Association for Traditional Chinese Medicine and Pharmacy Clinical Research Information Association, Branch of Chinese Medicine of China Association for Standardization. Preferred reporting items for comprehensive evaluation of Chinese patent medicine (PRICE-CPM). Chinese Journal of Evidence-Based Medicine, 2022, 22(7): 745-750. doi: 10.7507/1672-2531.202203157 Copy

1.	国家卫生健康委办公厅. 关于规范开展药品临床综合评价工作的通知. 中华人民共和国国家卫生健康委员会公报, 2021, (7): 21-28.
2.	Carroll C, Kaltenthaler E. Nature and reporting characteristics of UK health technology assessment systematic reviews. BMC Med Res Methodol, 2018, 18(1): 35.
3.	Enhancing the quality and transparency of health research. Available at: https://www.equator-network.org/.
4.	Moher D, Schulz KF, Simera I, et al. Guidance for developers of health research reporting guidelines. PLoS Med, 2010, 7(2): e1000217.
5.	孙凤. 医学研究报告规范解读. 北京: 北京大学医学出版社, 2015: 2-3.
6.	Makarski J, Brouwers MC, AGREE Enterprise. The AGREE Enterprise: a decade of advancing clinical practice guidelines. Implement Sci, 2014, 9: 103.
7.	Brouwers MC, Kerkvliet K, Spithoff K, et al. The AGREE reporting checklist: a tool to improve reporting of clinical practice guidelines. BMJ, 2016, 352: i1152.
8.	Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ, 2015, 350: g7647.
9.	AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care, 2003, 12(1): 18-23.
10.	Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol, 2007, 7: 10.
11.	国家食品药品监督管理局令. 药品说明书和标签管理规定. Available at: http://www.gov.cn/flfg/2006-03/16/content_228465.htm.
12.	国家中医药管理局. 关于印发中药、天然药物处方药说明书格式内容书写要求及撰写指导原则的通知. Available at: http://fjs.satcm.gov.cn/zhengcewenjian/2018-03-24/2624.html.
13.	张强, 王志飞, 谢雁鸣, 等. 中成药临床综合评价技术规范. 世界中医药, 2021, 16(22): 3394-3397,3403.
14.	王志飞, 张强, 谢雁鸣. 黄葵胶囊治疗慢性肾脏疾病的临床综合评价. 中国中药杂志, 2022, 47(6): 1484-1492.
15.	党海霞, 刘骏, 李兵, 等. 中成药价值评估指标体系研究. 中国新药杂志, 2021, 30(11): 961-970.
16.	李耿, 郭宇博, 李文姗, 等. 中药大品种科技竞争力报告(2019版)概要. 中国现代中药, 2020, 22(1): 1-20.
17.	廖星, 郭武栋, 曹庄, 等. 应用卫生技术评估开展中成药临床综合评价. 中国中药杂志, 2020, 45(16): 3749-3758.
18.	张强, 王志飞, 谢雁鸣, 等. 中成药临床综合评价报告规范. 中国中药杂志, 2021, 46(23): 6062-6067.

1. 国家卫生健康委办公厅. 关于规范开展药品临床综合评价工作的通知. 中华人民共和国国家卫生健康委员会公报, 2021, (7): 21-28.
2. Carroll C, Kaltenthaler E. Nature and reporting characteristics of UK health technology assessment systematic reviews. BMC Med Res Methodol, 2018, 18(1): 35.
3. Enhancing the quality and transparency of health research. Available at: https://www.equator-network.org/.
4. Moher D, Schulz KF, Simera I, et al. Guidance for developers of health research reporting guidelines. PLoS Med, 2010, 7(2): e1000217.
5. 孙凤. 医学研究报告规范解读. 北京: 北京大学医学出版社, 2015: 2-3.
6. Makarski J, Brouwers MC, AGREE Enterprise. The AGREE Enterprise: a decade of advancing clinical practice guidelines. Implement Sci, 2014, 9: 103.
7. Brouwers MC, Kerkvliet K, Spithoff K, et al. The AGREE reporting checklist: a tool to improve reporting of clinical practice guidelines. BMJ, 2016, 352: i1152.
8. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ, 2015, 350: g7647.
9. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care, 2003, 12(1): 18-23.
10. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol, 2007, 7: 10.
11. 国家食品药品监督管理局令. 药品说明书和标签管理规定. Available at: http://www.gov.cn/flfg/2006-03/16/content_228465.htm.
12. 国家中医药管理局. 关于印发中药、天然药物处方药说明书格式内容书写要求及撰写指导原则的通知. Available at: http://fjs.satcm.gov.cn/zhengcewenjian/2018-03-24/2624.html.
13. 张强, 王志飞, 谢雁鸣, 等. 中成药临床综合评价技术规范. 世界中医药, 2021, 16(22): 3394-3397,3403.
14. 王志飞, 张强, 谢雁鸣. 黄葵胶囊治疗慢性肾脏疾病的临床综合评价. 中国中药杂志, 2022, 47(6): 1484-1492.
15. 党海霞, 刘骏, 李兵, 等. 中成药价值评估指标体系研究. 中国新药杂志, 2021, 30(11): 961-970.
16. 李耿, 郭宇博, 李文姗, 等. 中药大品种科技竞争力报告(2019版)概要. 中国现代中药, 2020, 22(1): 1-20.
17. 廖星, 郭武栋, 曹庄, 等. 应用卫生技术评估开展中成药临床综合评价. 中国中药杂志, 2020, 45(16): 3749-3758.
18. 张强, 王志飞, 谢雁鸣, 等. 中成药临床综合评价报告规范. 中国中药杂志, 2021, 46(23): 6062-6067.

Next Article
Guideline for multi-dimensional and multi-criteria comprehensive evaluation of Chinese patent medicine

Chinese Journal of Evidence-Based Medicine

Preferred reporting items for comprehensive evaluation of Chinese patent medicine (PRICE-CPM)

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content